Latest Mergers And Acquisitions News

Spartan Resources Limited shares have been suspended from the ASX following court approval of a scheme of arrangement for its acquisition by Ramelius Resources Limited. This marks a significant step toward the consolidation of gold mining assets in Western Australia.

Nordic Resources has completed a major acquisition of three advanced gold projects in Finland, lifting its total gold equivalent resources to 1.23 million ounces. The company also secured A$3.5 million in institutional funding and appointed a seasoned mining executive as Chairman.

Polymetals Resources has updated its June 2025 quarterly cash flow report, confirming nearly two quarters of funding and ongoing revenue from concentrate sales. The company’s financing position remains stable amid planned equity issuance.

Adherium Limited has appointed seasoned medtech executive Dawn Bitz as CEO to spearhead the expansion of its Hailie® respiratory monitoring platform, with a strong focus on the US market.

The Supreme Court of Western Australia has approved the scheme of arrangement for Ramelius Resources to acquire Spartan Resources, marking a significant consolidation in the gold mining sector.

Bod Science reports a solid net cash inflow of $858,000 in Q4 FY2025, driven by R&D incentives and Biortica funding, while awaiting shareholder approval to complete a key acquisition.

Bod Science Limited reports a positive cash flow quarter driven by customer receipts, an R&D tax incentive, and proceeds from intellectual property sales, while navigating its Deed of Company Arrangement.

Nico Resources Limited reported steady progress on its Wingellina nickel-cobalt project despite challenging market conditions, completing a $1.1 million share placement and advancing metallurgical and drilling programs.

Norwest Minerals has reported a substantial 33% increase in its Bulgera Gold Project resource to 288,400 ounces and secured $4.85 million to advance exploration, including a new drilling campaign targeting deeper gold zones.

Inhalerx Limited has drawn $247,000 from a $38.5 million funding facility to advance clinical trials for its IRX-211 and IRX-616a drug candidates, reporting positive operating cash flow for the quarter ending June 2025.

InhaleRx Limited has secured key ethics approvals and initiated manufacturing for its inhaled drug candidates targeting breakthrough cancer pain and panic disorder, supported by a $38.5 million funding facility to accelerate development.

Dollarama Inc. has officially acquired The Reject Shop, paying shareholders $5.91 per share and triggering the retailer's imminent delisting from the ASX.